1Silverberg DS,Wexler D,Blum M,et al.The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe,resistant congestive heart failure improves cardiac and renal function and functional cardiac class,and markedly reduces hospitalizations.J Am Coll Cardiol,2000,35(7):1737-1744.
2Gilbertson D,Li S,Murray AM,et al.Competing risks of death vs ESRD in Medicare beneficiaries age 65P with chronic kidney disease CHF and anemia.J Am Soc Nephrol,2002,13:SA848.
3Tabbibizar R,Maisel A.The impact of B-type natriuretic peptide levels on the diagnoses and management of congestive heart failure.Curr Opin Cardiol,2002,17(4):340-345.
5Eriksen R,Vegsundvaag J,Hole T,et al.Hepatic and renal haemodynamic changes in congestive heart disease.Tidsskr Nor Laegeforen,2006,126(6):743-746.
6Petersson M,Friberg P,Eisenhofer G,et al.Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure.Eur Heart J,2005,26(9):906-913.
7Luchner A,Hengstenberg C,Lowel H,et al.Effect of compensated renal dysfunction on approved heart failure markers:direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP.Hypertension,2005,46(1):118-123.
8Coca SG,Perazella MA.The role of aldosterone blockers in the management of chronic heart failure.Am J Med Sci,2005,330(4):176-183.
9Hillege HL,Girbes AR,de Kam PJ,et al.Renal function,neurohormonal activation,and survival in patients with chronic heart failure.Circulation,2000,102(2):203-210.
10Dries DL,Exner DV,Domanski MJ,et al.The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction.J Am Coll Cardiol,2000,35(3):681-689.
